Events

OncoSil Medical (ASX:OSL) has announced encouraging preliminary results from its PANCOSIL Phase 1–2 Investigator Initiated Study, marking a potential breakthrough in the treatment of locally advanced pancreatic cancer.

Clinical-stage biotechnology company PYC Therapeutics (ASX:PYC) has announced a leadership transition, with Chair Alan Tribe appointed as Managing Director following the resignation of Dr Rohan Hockings, who has served as Chief Executive Officer and Executive Director since 2018.

BlinkLab (ASX:BB1) has announced the addition of the Thompson Center for Autism and Neurodevelopment at the University of Missouri as the sixth US clinical site for its pivotal FDA 510(k) diagnostic trial.

EMVision Medical Devices (ASX:EMV) has strengthened its growth trajectory with firm commitments for a $12 million capital raising, receiving strong backing from institutional, sophisticated, and professional investors.

Island Pharmaceuticals (ASX:ILA) has announced compelling new preclinical data demonstrating the potential of its broad-spectrum antiviral Galidesivir to combat two of the world’s most lethal viral threats, Marburg and Ebola.

CSL (ASX:CSL) has announced a deal with Dutch biotech VarmX to advance a new therapy designed to restore blood clotting in patients taking Factor Xa (FXa) inhibitors, a widely prescribed class of anticoagulants.

Australian company Alterity Therapeutics (ASX:ATH) has announced encouraging results from its Phase 2 trial of ATH434, a first-in-class therapy for Multiple System Atrophy.

Actinogen Medical (ASX:ACW) has reached a critical regulatory milestone in its bid to bring a novel Alzheimer’s treatment to market, securing agreement with the US FDA on the path forward for its lead therapy, Xanamem (emestedastat).

Australian biotech Cleo Diagnostics (ASX:COV) has taken a step forward in its bid to bring an innovative ovarian cancer triage test to market, following positive guidance from the US Food and Drug Administration.

Australian digital health company Adherium (ASX:ADR) has reported striking interim results from a large-scale US study showing its Hailie Smartinhaler can transform outcomes for people living with chronic respiratory conditions such as asthma and COPD.

AVITA Medical (ASX:AVH) has achieved a significant milestone with the granting of the CE Mark under the European Union Medical Device Regulation for its next-generation wound care device, RECELL GO.

Arovella Therapeutics (ASX:ALA) has reinforced its commitment to sustainable business practices with the release of its fourth Environmental, Social, and Governance Report, outlining progress in governance, environmental responsibility, social impact, and long-term value creation.